Looks like no one added any tags here yet for you.
parkinsons risk factors
advanced age, genetics, environmental exposures
parkinsons protective factors
caffeine, cigarette smoking, aerobic exercise (?)
pathophys of parkinsons
a complex interplay of several cellular processes lead to neuronal damage
toxic biochemical rxns leading to oxidative stress
abnormal cell signalling pathways that result in spontaneous cell death (i.e apoptosis)
dysfxnal protein degradation systems resulting in cytoplasmic protein accumulation and misfolded proteins
List the clinical presentation sx of parkinsons
Tremor
Rigidity
Akinesia/Bradykinesia
Postural Instability
How is a true parkinsons diagnosis established
must have akinesia/bradykinesia + one of the other three symptoms
Explain the tremor present in parkinsons
occurs at rest and is a pill rolling tremor
often intermittent in early stages
occurs most often in upper extremities, but may be evident in legs, lips, jaw, tongue (rarely involves the head)
explain rigidity in parkinsons
Resistance to passive movement
increased muscle tone
pts often complain of stiffness and pain
can have lead piped rigidity or cogwheel rigidity
reduced arm swing and stooped posture are often indicative of rigidity
lead pipe rigidity
a consistent state of rigitidy throughout full ROM
cogwheel rigidity
ratchet like stop and start movement pattern
occurs if concomitant tremor
explain akinesia/bradykinesia sx of parkinsons
generalized slowing of movement w/ loss of amplitude
very debilitating and occurs in all pts
typically occurs first in digits of upper extremeties: difficulty w/ ADLs, micrographia
in lower extremities- presents as shuffling gait or dragging of the feet/legs
explain postural instability sx of parkinsons
centrally-mediated postural reflexes become dampened
pts experience a feeling of imbalance, increasing fall risk
occurs later in disease process
pattern in which sx occur initially in parkinsons
asymmetrical, unilateral
examples of meds which can cause parkinsonism
antipsychotics
metoclopramide
lithium
SSRIs
CCBs
valproic acid
how to do a differential diagnosis for med-induced parkinsonism
is there a temporal relationship
occurs within 3mo of med start/dose increase but may be delayed up to a year (therefore hard to tell if temporal)
are the symptoms symmetrical
meds will cause bilateral sx but parkinsons causes unilateral initially
does the sx respond to med d/c
d/c med
Sx may take 7 days-several mo to resolve therefore difficult to tell
do they have dopaminergic neuron loss sx
loss of sense of smell (bc of DA neuron loss) is prob not med induced, prob real parkinsons
PD treatment is targeted at doing what
Sx control
non pharm
patient education (parkinson.ca)
regular exercise: aerobic, strength, balance and gait training
speech, occupational and physical therapy
surgical options: lesioning procedures, deep brain stimulation
3 main things to consider when deciding on parkinsons Tx
severity/impact on QoL
type of Sx
age
If someone has no/minimal sx or fxnal impairment what are treatment options?
watch and wait
MAO-B inhibitor
amantadine
anticholinergics
what type of patient is anticholinergics rx for
younger, tremor predominent (no significant bradykinesia)
Ex of MAO-B inhibitors
Selegiline, Rasagiline, Safinamide
Problem with Selegiline
structurally similar to amphetamines therefore can cause insomnia
how to avoid/fix insomnia with selegiline
second dose given @ noon or v early afternoon
Which MAO-B inhibitor causes the most confusion
selegiline
Which MAO-B inhibitor is most commonly used + why
Rasagiline due to once daily dosing and it is well tolerated
Which MAO-B inhibitor is most potent
rasagiline
When is Safinamide used
add on therapy for treatment of wearing off (not commonly used)
AE of MAO-B inhibitors
vivid treams, dizziness, insomnia, constipation
Drug interactions with MAO-B inhibitors and their management
SSRIs/serotonergic agents
MAOB inhibitor is v selective to MAOB which primarily affects DA.
May see combined with SSRI as depression is v common comorbidity
Monitor for serotonin syndrome, do risk v benefit assessment, check for other serotonin meds on file
Tyramine containing foods
can have up to 75mg tyramine
should give them chart on tyramine foods
ex of anticholinergics used for parkinsons
benztropine
trihexyphenidyl
most common anticholinergic used
benztropine
Who should anticholinergics not be used in
not the DOC for 65+ And dementia (bc of AE’s)
should not be used in pts with dyskinesias or other motor fluctuations
AE anticholinergics
constipation, dry mouth, urinary retention, blurred vision, confusion/cognitive impairment
who is more susceptible to anticholinergic induced cognitive impairment
elders, esp those w/ dementia
how to d/c all agents used in PD
slowly taper
drug options for Mild parkinsons Sx/fxnal impairment
Levodopa-carbidopa
dopamine-agonist
Tx options for those <50 + mild parkinons Sx
levodopa-carbidopa OR dopamine agonist
Tx options for those 50+ and mild parkinsons Sx
levodopa-carbidopa
minimal target dose of levodopa-carbidopa
100/25mg TID or higher
safety/efficacy comparison of LD and dopamine agonists
LD has more motor ae but more effective sx control
dopamine agonists are more likely to cause non motor AEs (including GI aes)
why should you not abruptly D/C dopaminergic agents
NMS like sx
Big difference between LD and controlled release LD
controlled release has bioavailability 70% of IR agent therefore may need 30% dose increase
only have to dose BID therefore may be used earlier in Dx
LD central ae
hallucinations, confusion, drowsiness, dyskinesias
peripheral LD ae
nausea, orthostasis
carbidopa fxn in LD
helps with peripheral AE (nausea, orthostasis) because it blocks peripheral conversion of L-dopa to dopamine which causes dopamine to not be able to cross BBB (we want it to) therefore causes these peripheral ae
target daily dose of carbidopa
70+mg
why do we have a target minimal dose for carbidopa
to prevent peripheral conversion of levodopa
How to administer LD
taking w/ food can help N/V
BUT: avoid taking w/ large meals (delays onset) and avoid protein (competes w/ L-dopa to cross BBB on transporters)
space from iron by 2hr
examples of dopamine agonists
Pramipexole
Ropinirole
Rotigotine
LD vs dopamine agonists: why has less frequent administration
dopamine agonists usually
unique dosage form available w/ dopamine agonists
Rotigotine- transdermal patch
AE dopamine agonists
hallucinations, impulse control disorders, somnolence, edema, weakness
If someone is intolerent to one dopamine agonist what can you do
can try another
if patient is unresponsibe to LD can you try dopamine agonists
no they usually wont respond, if someone has PD it should respond to LD therefore reassess diagnosis
If someone has mod/severe PD sx what agent to try
levodopa-carbidopa
1st motor complication that generally occurs with PD
wearing off phenominom
questions to ask to assess wearing off
do you feel your med works as well for you as it has in the past
about how long after you take LD do your Sx appear
can you describe your Sx for me
how do you take your LD
evaluate adherence and proper administration
if someone is experiencing wearing off when do Sx usually return
3-4hr post LD dose
sx of wearing off
re emergence of pts typical PD sx: tremor, bradykinesia, rigidity
tremor- more rhythmic in nature and occur around one joint
Vs a dyskinesia- tends to be more disordered, resembling writhing movements
list management options for wearing off of LD
Increase dose and/or frequency of LD
sub or add controlled release LD
add a MAOB inhibitor
add a COMT inhibitor
add a dopamine agonist
Good first strategy for pts experiencing wearing off with LD who are on low dose and not experiencing peak dose dyskinesia
increase dose and/or frequency
what is dose fractionation
lower the individual dose of LD and admin more frequently
When is dose fractionation used
in more advanced PD, where pt is experiencing wearing off but peak dose dyskinesia may be a concomitatant issue
When should you sub or add controlled release LD
patients experiencing wearing off in middle of night/early AM
not recommended for daytime management
cons of controlled released LD
may result in unpredictable responses, including delayed onset dyskinesia
not absorbed aswell as IR tabs making individual dose increases of approx 30% needed in some cases
When/why is it a good idea to add MAOB inhibitor to LD
effective adjunct therapy for treating motor complications
thought to prolong t1/2 of DA and reduce wearing off
which MAOB inhibitors are usually added to LD
rasagiline, safonamide
ex of COMT inhibitor
Entacapone
Why are COMT inhibitors not used as initial management for PD
does nothing on its own and has to be with LD to be effective
AE of COMT inhibitors
may cause peak dose dyskinesia
profuse diarrhea, hallucinations, syncope
brown-orange discoloration of urine, or teeth if tab is bitten
LFTs should be performed q 6mo (sometimes causes liver dysfxn)
effect of COMT inhibitors
may increase “on time” of LD by about 1-2hr per day - may need to reduce LD by 10-30%
How to add a dopamine agonist to LD
initiate @ lowest possible dose + titrate slowly to reduce risk of DA ae’s
LD doses may need to be initially reduced
what population may you want to avoid adding dopamine agonist to LD in
65+ or those with cognitive impairment
Sx of peak dose dyskinesia
Chorieform in nature- large amplitude, twisting/turning, jerky movements
not repetitive or rhythmic
how long after taking dose of LD would peak dose dyskinesia appear
30-90min post dose
options for managing peak dose dyskinesia
add amantadine
reduce dose of LD or other adjunctive Tx
if taking CR LD switch to IR
What should be the first intervention if peak dose dyskinesia occurs
switch CR LD → IR
How to manage peak dose dyskinesia while preventing wear off
dose fractionation (reduce LD dose and admin more freq)
If wearing someone gets peak dose dyskinesia and you try to manage it w/ dose fractionation but they get wearing off anyways what can you do
add dopamine agonist bc it is less likely to cause dyskinesia than LD
If someone is on LD + multiple therapies and is getting peak dose dyskinesia what can you do
reduce or d/c MAOB inhibitor or entacapone
what should be tried before adding amantadine for peak dose dyskinesia
attempt dose reduction of other dopaminergic agents
Why is amantadine not often used when no/minimal sx of PD
bc there is little evidence to support use in early PD and efficacy may decrease in 1-2yrs so its better to save for later
AE amantadine
usually well tolerated
elderly pts may be more susceptible to confusion and hallucinations
peripheral ae
livedo reticularis
ankle/pedal edema
how to Tx GI motility issues in PD
apply general measures for Tx constipation:
increase fluid and fibre intake
physical activity
PEG, psyllium, lactulose
reassess anticholinergic meds
Domperidone (NOT metoclopramide)
Depression options in PD
TCAs- added benefit of anticholinergic properties for tremor
SSRI/SNRI- prefered bc of AE profile but may exacerbate tremor or other motor features (dystonia, akathisia)
meds used for psychosis in PD
Clozapine
most evidence
requires strict hematologic monitoring
bad ae profile
may reduce tremor
QTP
used most often
v well tolerated
which antipsychotics are not used in PD due to ae profile
risperidone and olanzapine
How to distinguish PD from dementia w/ lewy bodies
If Sx of dementia occur more than 1yr after PD sx: diagnose with PD
If Sx of dementia occur <1yr after PD sx: diagnose with lewy body dementia
how to Tx dementia Sx in PD
cholinesterase inhibitors- donepezil and rivastigme
con of cholinesterase inhibitors in PD
may worsen PD sx mainly tremor
Which cholinesterase inhibitor has slightly more efficacy in dementia in PD patients
Rivastigmine
which cholinesterase inhibitor is better tolerated in PD
donepezil
How to manage orthostasis in PD
avoid aggravating factors- large meals, alcohol, warm environments
increase salt intake
tilt head up at night
compression stockings
if no response to nonpharm can use fludrocortisone or midodrine
domperidone for postprandial hypotension